HOME >> BIOLOGY >> NEWS
Ketek (Telithromycin) highly active in vitro against Streptococcus pneumoniae

A novel investigational antibiotic has demonstrated excellent in vitro activity against isolates of Streptococcus pneumoniae (S. pneumoniae), including those resistant to penicillin, macrolide or fluoroquinolone antibiotics according to a study presented today. In vitro data from the international PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) study presented today at the 11th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), suggest that Ketek (telithromycin) may be an effective option for the treatment of community acquired respiratory tract infections (CARTIs), particularly those caused by Streptococcus pneumoniae, the most common pathogen associated with CARTIs.

CARTIs are the most common infections treated by healthcare practitioners and represent a significant societal burden, causing 50 million deaths globally each year. As part of the worldwide PROTEKT study, bacterial isolates from patients with community-acquired pneumonia (CAP), acute bacterial exacerbation of chronic bronchitis (AECB), acute sinusitis, tonsillitis/pharyngitis or acute otitis media were collected from centres throughout the world. As of January 2001, the in vitro analysis of more than 5000 isolates collected in the PROTEKT study has confirmed the alarming spread of antimicrobial resistance among the pathogens most frequently implicated in CARTIs.

The study revealed that the overall worldwide prevalence of penicillin (PEN) resistance among pneumococci was 39.9%. Levels differed markedly among countries with South Korea recording the highest levels (80.5%). High levels of PEN resistance were also evident in Japan (65.6%), Hong Kong (58.6%), France (59.4%), Spain (43.7%) and the USA (43.6%).

The study also shows that erythromycin (ERY) resistance was highest in Asia (combined ERY resistance of 86.2%, 80.5% and 72.9% in South Korea, Japan and Hong Kong, respectively), and more than half of
'"/>

Contact: Liz Rickard
elizabeth.rickard@ketchum.com
44-0-20-7611-3633
Ketchum
3-Apr-2001


Page: 1 2 3

Related biology news :

1. Ketek receives marketing approval in Europe
2. Ketek effective against respiratory tract infections with reduced susceptibility to other antibiotics
3. Byproduct of water-disinfection process found to be highly toxic
4. NIST study shows computerized fingerprint matching is highly accurate
5. Asian bird flu became highly pathogenic through continued circulation and gene swapping
6. New compound highly efficacious at reducing human tumour growth
7. UT Southwestern researchers define regions of human genes highly prone to mutation
8. More dialysis, highly permeable artificial kidney may not aid some, UT Southwestern researcher finds
9. With help from the Office of Naval Research, a right whale pied "Piper" shows the way to recovery for this highly endangered species
10. A highly conserved mechanism used during the development of zebrafish and fruitfly eyes points to a common evolutionary origin of animal eyes
11. Seafloor off Mid-Atlantic coast highly charged with gas

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... ... September 03, 2020 , ... ... announced that an extensive third-party assessment of the company’s security practices has been ... against federal security regulations. The comprehensive evaluation reviewed Litmus’ processes and systems, assessing ...
(Date:8/26/2020)... ... August 25, 2020 , ... ... targeting mitochondria, in partnership with Essex Bio-Technology, a bio-pharmaceutical company specializing in ... 3 VISTA-2 study of SkQ1 ophthalmic solution in patients with moderate to ...
(Date:8/26/2020)... (PRWEB) , ... August 25, 2020 , ... Modality ... made Inc. magazine’s 2020 annual Inc. 5000 list. The list is the most prestigious ... in 2019 as well, and for this year’s list, reported three-year revenue growth of ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... , ... August 11, 2020 , ... ... year to expand the Facioscapulohumeral Muscular Dystrophy Clinical Trial Research Network ... and 2022. The network is a consortium of academic research centers in the ...
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, a highly ... closed on the purchase of greenfield for a new, expanded manufacturing facility. The ... 21 acres in the initial acquisition, with an option to purchase an additional ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... that can combine up to three different materials for use with CRM, neurostimulation, ... up to three materials to meet specific design requirements, performance, and cost criteria; ...
Breaking Biology Technology:
Cached News: